Percutaneous Left Atrial Appendage Closure with the LAmbre Device Protected by a Cerebral Protection System in a 76-Year-Old Man with Persistent Left Atrial Appendage Thrombus

Sorin Ștefan Popescu, Christian Hendrik Heeger, Ahmad Keelani, Roland Richard Tilz*

*Korrespondierende/r Autor/-in für diese Arbeit

Abstract

Patient: Male, 76-year-old Final Diagnosis: Left atrial appendage thrombus despite optimal anticoagulation Symptoms: Palpitations Medication: — Clinical Procedure: Cryoballoon-based ablation • percutaneous left atrial appendage closure • transesopha-geal echocardiogram Specialty: Cardiology Objective: Background: Case Report: Conclusions: Unusual clinical course Despite use of optimal oral anticoagulation regimens, left atrial appendage (LAA) thrombus may develop and persist in patients with atrial fibrillation (AF). The therapeutic options in this population are limited. Percutaneous LAA closure (LAAC) is performed to reduce thrombus formation and the risk of thromboembolism. However, this approach is prohibited in patients with LAA thrombus. We report the case of a 76-year-old man with AF and persistent LAA thrombus who underwent percutaneous LAAC with the LAmbre device protected by the SENTINEL Cerebral Protection System (CPS). A 76-year-old man with history of persistent AF treated with pulmonary veins and LAA isolation developed LAA thrombus resistant to different anticoagulation therapies, including apixaban and Phenprocoumon, with a target international normalized ratio (INR) of 3-3,5. Repeated follow-up transesophageal echocardiography showed a persistent LAA thrombus despite optimal INR values. Thus, we performed a percutaneous LAAC using a double-umbrella-designed appendage occluder and a CPS to minimize the risk of intraprocedural cerebral embolization. The procedure was guided by transesophageal echocardiography and fluoroscopy. No signs of systemic thromboembolism were noted, and the CPS filters showed no evidence of thrombotic material. This report shows that the use of a CPS during percutaneous LAAC may reduce the risk of procedural cerebral embolization and could be used as an alternative therapy for patients with contraindication or lack of effec-tiveness of oral anticoagulation.

OriginalspracheEnglisch
Aufsatznummere937063
ZeitschriftAmerican Journal of Case Reports
Jahrgang23
DOIs
PublikationsstatusVeröffentlicht - 2022

Strategische Forschungsbereiche und Zentren

  • Zentren: Universitäres Herzzentrum Lübeck (UHZL)

DFG-Fachsystematik

  • 205-12 Kardiologie, Angiologie

Zitieren